[
  {
    "ts": null,
    "headline": "Top Stock Reports for Apple, Eli Lilly & Visa",
    "summary": "Apple's strong Services growth, Eli Lilly's GLP-1 momentum, and Visa's digital expansion headline today's top stock reports.",
    "url": "https://finnhub.io/api/news?id=61d183e4eb7f53c15fe6741254730a10161bf14157b6958dd1bf953601abb40f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760386500,
      "headline": "Top Stock Reports for Apple, Eli Lilly & Visa",
      "id": 137074232,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Apple's strong Services growth, Eli Lilly's GLP-1 momentum, and Visa's digital expansion headline today's top stock reports.",
      "url": "https://finnhub.io/api/news?id=61d183e4eb7f53c15fe6741254730a10161bf14157b6958dd1bf953601abb40f"
    }
  },
  {
    "ts": null,
    "headline": "1 Cash-Producing Stock to Target This Week and 2 That Underwhelm",
    "summary": "A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.",
    "url": "https://finnhub.io/api/news?id=790ec29543de6df97482a17d698911c11a12a620f7e46976dc1c355584e525d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760374647,
      "headline": "1 Cash-Producing Stock to Target This Week and 2 That Underwhelm",
      "id": 137068659,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.",
      "url": "https://finnhub.io/api/news?id=790ec29543de6df97482a17d698911c11a12a620f7e46976dc1c355584e525d8"
    }
  },
  {
    "ts": null,
    "headline": "Moderna (MRNA) Stock Trades Up, Here Is Why",
    "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped in the afternoon session after the company presented promising early data for its investigational cancer antigen therapy, mRNA-4359, from a Phase I/II study.",
    "url": "https://finnhub.io/api/news?id=14a1c4d1d49348a5fa3be74c01f651f036708b33e72a4dde7764119a6862ffcf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760372519,
      "headline": "Moderna (MRNA) Stock Trades Up, Here Is Why",
      "id": 137068660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped in the afternoon session after the company presented promising early data for its investigational cancer antigen therapy, mRNA-4359, from a Phase I/II study.",
      "url": "https://finnhub.io/api/news?id=14a1c4d1d49348a5fa3be74c01f651f036708b33e72a4dde7764119a6862ffcf"
    }
  },
  {
    "ts": null,
    "headline": "How Keytruda’s Subcutaneous FDA Approval and Extended Patent Could Shape Merck’s (MRK) Investment Trajectory",
    "summary": "In early October 2025, Merck announced FDA approval for a subcutaneous version of Keytruda and shared positive Phase 3 trial outcomes for both Keytruda in several cancer types and Winrevair in pulmonary arterial hypertension, with new research presented at the ESMO Congress in Berlin. The subcutaneous Keytruda formulation extends the drug's patent protection beyond 2028 while enhancing patient and provider convenience, a significant move to reinforce Merck’s oncology leadership amid stiff...",
    "url": "https://finnhub.io/api/news?id=edcbe5441b6fc9964b04357c992c00357d769273e2b9e663a76754df83ebdb72",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760371834,
      "headline": "How Keytruda’s Subcutaneous FDA Approval and Extended Patent Could Shape Merck’s (MRK) Investment Trajectory",
      "id": 137068661,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "In early October 2025, Merck announced FDA approval for a subcutaneous version of Keytruda and shared positive Phase 3 trial outcomes for both Keytruda in several cancer types and Winrevair in pulmonary arterial hypertension, with new research presented at the ESMO Congress in Berlin. The subcutaneous Keytruda formulation extends the drug's patent protection beyond 2028 while enhancing patient and provider convenience, a significant move to reinforce Merck’s oncology leadership amid stiff...",
      "url": "https://finnhub.io/api/news?id=edcbe5441b6fc9964b04357c992c00357d769273e2b9e663a76754df83ebdb72"
    }
  },
  {
    "ts": null,
    "headline": "Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?",
    "summary": "Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=7ce56c37d0f957f408edac919bffbc6bcbc365fe1ffcd35858c142d8cfed47d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760371802,
      "headline": "Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?",
      "id": 137068662,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=7ce56c37d0f957f408edac919bffbc6bcbc365fe1ffcd35858c142d8cfed47d3"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Merck (MRK) is a Strong Momentum Stock",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=fb1a3aee24291c84e813d1aedadeea0d2b54882982d9b4f7945b549023fa6e8a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760363401,
      "headline": "Here's Why Merck (MRK) is a Strong Momentum Stock",
      "id": 137068663,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=fb1a3aee24291c84e813d1aedadeea0d2b54882982d9b4f7945b549023fa6e8a"
    }
  },
  {
    "ts": null,
    "headline": "Merck Completes $10B Acquisition of Verona Pharma, Adds COPD Drug Ohtuvayre",
    "summary": "Merck & Co. Inc. (NYSE:MRK) is one of the best growth stocks to buy now. On October 7, Merck & Co. announced the completion of its acquisition of Verona Pharma (NASDAQ:VRNA). Verona Pharma is now a wholly-owned subsidiary of Merck. The acquisition is valued at ~$10 billion and was executed under the terms of an […]",
    "url": "https://finnhub.io/api/news?id=877d9f14cb96b61ec96ca6d7dd6d929ddfa2ed5682f94b62b3fcfa4046ae52a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760362132,
      "headline": "Merck Completes $10B Acquisition of Verona Pharma, Adds COPD Drug Ohtuvayre",
      "id": 137068664,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co. Inc. (NYSE:MRK) is one of the best growth stocks to buy now. On October 7, Merck & Co. announced the completion of its acquisition of Verona Pharma (NASDAQ:VRNA). Verona Pharma is now a wholly-owned subsidiary of Merck. The acquisition is valued at ~$10 billion and was executed under the terms of an […]",
      "url": "https://finnhub.io/api/news?id=877d9f14cb96b61ec96ca6d7dd6d929ddfa2ed5682f94b62b3fcfa4046ae52a4"
    }
  },
  {
    "ts": null,
    "headline": "Merck Initiates Three New Phase 2b Trials for Investigational Inflammatory Drug Tulisokibart",
    "summary": "Merck & Co. Inc. (NYSE:MRK) is one of the most promising stocks under $100. On October 6, Merck & Co. announced the initiation of three new Phase 2b trials for tulisokibart (MK-7240). Tulisokibart is an investigational humanized monoclonal antibody targeting tumor necrosis factor/TNF-like cytokine 1A/TL1A. The program expansion reflects Merck’s ongoing commitment to immune-mediated inflammatory […]",
    "url": "https://finnhub.io/api/news?id=6bac84ab156788b200dedd2b34d807ac3ab852118779e4b9296f7b5bea781d6c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760359434,
      "headline": "Merck Initiates Three New Phase 2b Trials for Investigational Inflammatory Drug Tulisokibart",
      "id": 137066374,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co. Inc. (NYSE:MRK) is one of the most promising stocks under $100. On October 6, Merck & Co. announced the initiation of three new Phase 2b trials for tulisokibart (MK-7240). Tulisokibart is an investigational humanized monoclonal antibody targeting tumor necrosis factor/TNF-like cytokine 1A/TL1A. The program expansion reflects Merck’s ongoing commitment to immune-mediated inflammatory […]",
      "url": "https://finnhub.io/api/news?id=6bac84ab156788b200dedd2b34d807ac3ab852118779e4b9296f7b5bea781d6c"
    }
  },
  {
    "ts": null,
    "headline": "Merck: An Undervalued Stock In An Expensive Market",
    "summary": "Merck increased its revenue from $39.5 billion in FY 2015 to $64.2 billion in FY 2024. Thatâs a compound annual growth rate of 5.5%. See why I rate MRK stock a buy.",
    "url": "https://finnhub.io/api/news?id=a08cab6ce3479041e6c9f2e6a8cbb31a0561475197938fb4f299be686895d090",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760349600,
      "headline": "Merck: An Undervalued Stock In An Expensive Market",
      "id": 137067393,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck increased its revenue from $39.5 billion in FY 2015 to $64.2 billion in FY 2024. Thatâs a compound annual growth rate of 5.5%. See why I rate MRK stock a buy.",
      "url": "https://finnhub.io/api/news?id=a08cab6ce3479041e6c9f2e6a8cbb31a0561475197938fb4f299be686895d090"
    }
  }
]